Metformin use is associated with a lower risk of uterine leiomyoma in female type 2 diabetes patients.

ABSTRACT:

Background

Whether metformin may reduce the risk of uterine leiomyoma in type 2 diabetes patients has not been investigated. This retrospective cohort study compared the risk of uterine leiomyoma in ever versus never users of metformin.

Methods

Female patients with new-onset type 2 diabetes during 1999-2005 were enrolled from the reimbursement database of Taiwan's National Health Insurance and followed up from 1 January 2006 until 31 December 2011. Analyses were conducted in a propensity score (PS) matched-pair cohort of 10,998 ever users and 10,998 never users of metformin. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the PS.

Results

A total of 321 never users and 162 ever users developed

SUBMITTER: Tseng CH 

PROVIDER: S-EPMC6920594 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature